Progyny, Inc. (NASDAQ:PGNY) Stock Holdings Lessened by Hussman Strategic Advisors Inc.

Hussman Strategic Advisors Inc. lowered its stake in Progyny, Inc. (NASDAQ:PGNY) by 60.0% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 42,000 shares of the company’s stock after selling 63,000 shares during the period. Hussman Strategic Advisors Inc.’s holdings in Progyny were worth $724,000 as of its most recent filing with the SEC.

Several other institutional investors also recently modified their holdings of the stock. GAMMA Investing LLC increased its holdings in shares of Progyny by 341.4% in the fourth quarter. GAMMA Investing LLC now owns 1,611 shares of the company’s stock valued at $28,000 after buying an additional 1,246 shares in the last quarter. Nisa Investment Advisors LLC increased its holdings in shares of Progyny by 108.4% in the fourth quarter. Nisa Investment Advisors LLC now owns 2,934 shares of the company’s stock valued at $51,000 after buying an additional 1,526 shares in the last quarter. KBC Group NV increased its holdings in shares of Progyny by 84.6% in the fourth quarter. KBC Group NV now owns 4,669 shares of the company’s stock valued at $81,000 after buying an additional 2,140 shares in the last quarter. Entropy Technologies LP raised its stake in Progyny by 5.5% during the 4th quarter. Entropy Technologies LP now owns 47,883 shares of the company’s stock valued at $826,000 after purchasing an additional 2,499 shares during the period. Finally, Caitlin John LLC lifted its holdings in shares of Progyny by 2,974.8% in the fourth quarter. Caitlin John LLC now owns 3,290 shares of the company’s stock valued at $57,000 after purchasing an additional 3,183 shares in the last quarter. Institutional investors own 94.93% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently issued reports on PGNY. Barclays reduced their target price on Progyny from $30.00 to $17.00 and set an “overweight” rating for the company in a report on Thursday, November 14th. Canaccord Genuity Group reduced their target price on Progyny from $18.00 to $17.00 and set a “hold” rating for the company in a report on Wednesday, November 13th. JPMorgan Chase & Co. increased their target price on Progyny from $17.00 to $23.00 and gave the company a “neutral” rating in a report on Tuesday, January 28th. Truist Financial restated a “hold” rating and issued a $19.00 target price (down previously from $26.00) on shares of Progyny in a report on Wednesday, November 13th. Finally, Bank of America increased their target price on Progyny from $21.00 to $25.00 and gave the company a “buy” rating in a report on Tuesday, February 11th. Nine research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, Progyny currently has an average rating of “Hold” and an average target price of $25.83.

Insiders Place Their Bets

In other Progyny news, Chairman David J. Schlanger bought 150,000 shares of the stock in a transaction on Thursday, December 26th. The shares were purchased at an average cost of $14.68 per share, with a total value of $2,202,000.00. Following the completion of the transaction, the chairman now directly owns 228,269 shares of the company’s stock, valued at $3,350,988.92. This represents a 191.65 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Peter Anevski purchased 209,500 shares of the stock in a transaction dated Monday, December 23rd. The stock was acquired at an average cost of $14.48 per share, for a total transaction of $3,033,560.00. Following the completion of the transaction, the chief executive officer now owns 441,463 shares of the company’s stock, valued at $6,392,384.24. The trade was a 90.32 % increase in their position. The disclosure for this purchase can be found here. Company insiders own 12.30% of the company’s stock.

Progyny Price Performance

Progyny stock opened at $23.88 on Friday. The company has a market capitalization of $2.03 billion, a price-to-earnings ratio of 41.17, a PEG ratio of 2.28 and a beta of 1.34. Progyny, Inc. has a one year low of $13.39 and a one year high of $40.89. The company’s fifty day moving average price is $19.67 and its two-hundred day moving average price is $18.68.

Progyny Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.